PR Newswire Clinical TrialsOriginal article
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
PartnershipHM17321Positive
AI Analysis
Summary
Hanmi Pharmaceutical has signed an exclusive licensing agreement with Genentech for HM17321, a UCN2 analog being developed for chronic weight management and obesity, with a total deal value of up to $2.3 billion including upfront payments, milestones, and tiered royalties.
Importance:7/10
Sentiment:
0.70
licensing dealobesityweight managementHanmi PharmaGenentechpartnership
Read the original article
Published by PR Newswire Clinical Trials on August 24, 2026 4:40 AM